Experimental cell therapy tested for patients with severe transplant complications
NCT ID NCT07253259
Summary
This early-stage study is testing whether a new cell injection called GT729 is safe and might help control chronic graft-versus-host disease (cGVHD). The trial includes adults aged 18-65 who have cGVHD that hasn't responded to at least two previous treatments and who still need immune-suppressing medications. Researchers will monitor participants closely for side effects while checking if the treatment reduces their cGVHD symptoms.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CGVHD are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences
RECRUITINGTianjin, Tianjin Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.